An interventional study of Dumansız (Transtheoretical Model-Based Chatbot Support Intervention) in Smoking ( Cigarette), Smoking (Tobacco) Addiction and Smoking Behaviors, sponsored by Seher DÖNER. Active, not recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Seher DÖNER · Not applicable, Interventional, and Treatment
The purpose of this clinical trial is to examine the impact of a chatbot-supported intervention based on the Transtheoretical Model (TTM) on smoking behavior, self-efficacy, decisional balance, and the urge to smoke among university students. The main questions it aims to answer are:
Participants will:
132 studies on the registry are indexed under Cigarette Smoking; 60 are open to participants now.
This study's enrollment of 100 is close to the median of 94 across 114 interventional studies indexed under Cigarette Smoking.
Browse Cigarette Smoking studies →This is the only study on the registry with Seher DÖNER as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants assigned to this arm will receive a six-week, Transtheoretical Model-based, scenario-based, semi-interactive, rule-based chatbot intervention delivered via Telegram to support smoking behavior change. The intervention includes weekly interactive sessions and two brief informational or motivational messages per week. The chatbot content is designed to address participants' stage of change, smoking-related triggers, barriers to quitting, coping strategies, and self-efficacy.
Behavioral: Dumansız (Transtheoretical Model-Based Chatbot Support Intervention)
Participants assigned to this arm will not receive the chatbot intervention during the study period. They will complete the same assessments as the intervention group at baseline, immediately after the six-week intervention period, and at three-month follow-up. Smoking cessation educational material will be provided after completion of the final follow-up assessment. In addition, participants who wish to receive the chatbot intervention may be offered access to it after the study has ended.
"Dumansız" is a six-week, Transtheoretical Model (TTM)-based chatbot support intervention delivered via Telegram. The chatbot is scenario-based, semi-interactive, and rule-based; it does not use artificial intelligence or analyze free-text responses. Standardized responses are provided through predefined message flows and response options. Content is tailored to participants in the precontemplation, contemplation, or preparation stage of change. The intervention includes one interactive text-based session (approximately 5-10 minutes) and two brief informational or motivational messages per week, which may include text, videos, or educational materials. Stage of change is reassessed every two weeks, and message flows are adjusted when a participant's stage changes. The intervention draws on TTM processes of change and uses communication principles and techniques from motivational interviewing to support awareness, motivation, decisional balance, and self-efficacy.
Proportion of Participants Reporting Smoking Cessation at Week 6
Smoking cessation status will be assessed by participant self-report. The outcome is the proportion of participants who report having stopped smoking cigarettes at Week 6, compared between the intervention and control groups.
Time frame: At baseline, immediately after the six-week intervention (Week 6)
Change in Stage of Change for Smoking Cessation from Baseline to Week 6
Stage of change will be assessed using the Stage of Change Questionnaire based on the Transtheoretical Model. Participants will be classified into precontemplation, contemplation, preparation, action, or maintenance. Change in stage from baseline to Week 6 will be evaluated and compared between the intervention and control groups.
Time frame: Baseline and Week 6
Proportion of Participants Reporting Smoking Cessation at 3 Months After the 6-Week Intervention
The proportion of participants who report having stopped smoking 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 Months After the 6-Week Intervention
Change in Stage of Change for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention
Change in participants' stage of change for smoking cessation, classified as precontemplation, contemplation, preparation, action, or maintenance, from baseline to 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 months after completion of the 6-week intervention
Change in Smoking Cessation Self-Efficacy from Baseline to Week 6
Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to the end of the 6-week intervention period.
Time frame: Baseline and Week 6
Change in Smoking Cessation Self-Efficacy from Baseline to 3 Months After the 6-Week Intervention
Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 Months After the 6-Week Intervention
Change in Decisional Balance for Smoking Cessation from Baseline to Week 6
Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to Week 6.
Time frame: Baseline and Week 6
Change in Decisional Balance for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention
Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 Months After the 6-Week Intervention
Change in Cigarette Craving Scores from Baseline to Week 6
Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to Week 6.
Time frame: Baseline and Week 6
Change in Cigarette Craving Scores from Baseline to 3 Months After the 6-Week Intervention
Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 Months After the 6-Week Intervention
Change in Nicotine Dependence Scores from Baseline to Week 6
Change in participants' nicotine dependence scores, measured using the Fagerström Test for Nicotine Dependence (FTND), from baseline to Week 6.
Time frame: Baseline and Week 6
Change in Nicotine Dependence Scores from Baseline to 3 Months After the 6-Week Intervention
Change in participants' nicotine dependence scores, measured using the Fagerström Test for Nicotine Dependence (FTND), from baseline to 3 months after completion of the 6-week intervention.
Time frame: Baseline and 3 Months After the 6-Week Intervention
Participant Satisfaction with the Chatbot Intervention
Participants' satisfaction with the chatbot intervention will be assessed using a 5-point rating question ranging from 1 (not at all satisfied) to 5 (very satisfied). Participants' likelihood of recommending the intervention to a friend will be assessed using a rating scale ranging from 0 (not at all likely) to 10 (extremely likely).
Time frame: Week 6
Plan to share: No — Individual participant data will not be shared with other researchers due to participant confidentiality and data protection considerations. Study results will be reported in aggregate form, without identifying individual participants.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.
Of 64 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 53. This study's planned 5 months is below that.
Counting every sponsor, half of 66 studies reached it within 28 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.